top of page
Browse by category
Search


Syntis Bio reports SYNTIETY-1 outcomes demonstrating SYNT-101 mimics gastric bypass hormone response with placebo-like tolerability
Syntis Bio has announced that results from its Phase 1/1b SYNTIETY-1 trial of SYNT-101, an investigational once-daily tablet for obesity, were presented at The Obesity Society’s 44th Annual Meeting at ObesityWeek® 2026. Data from the trial demonstrated that SYNT-101 reproduced the meal-driven gut-hormone response of gastric bypass surgery, produced placebo-adjusted weight loss over 28 days, and was well tolerated, with gastrointestinal (GI) adverse events comparable to placeb
Browse by tag






bottom of page
